

OTCBB symbol: **AAFS**
Data as of 4/8/09 closing.
Bid **2.50** x **3.25** ask.

Across America Financial Services, Inc.

Last Trade Price	\$ 3.20	<i>Shares Authorized</i>	
52-Week Range	\$.20-2.00	Common Shares	200,000,000
Daily High	\$ 3.50	Preferred Shares	1,000,000
Daily Low	\$ 1.25	<i>Shares Outstanding</i>	
Market Capitalization	\$ 6.28 M	Common Shares	23,764,567
Average Volume (3 mo.)	174.603	Preferred Shares	0

Business Summary

BACKGROUND AND HISTORY

The Company was incorporated under Colorado law on December 1, 2005 as a wholly-owned subsidiary of Across America Real Estate Corp. In March 2007, the Company filed a form SB-2 registration statement with the SEC to register the spin-off of the shares of the Company to the shareholders of Across America Real Estate Corp. The registration statement was subsequently declared effective and the spin-off was completed on or about March 23, 2007. The Company intended to act as a mortgage broker for commercial real estate transactions. However, no revenues were ever generated from this business.

Apro was formed as a Colorado corporation on December 26, 2006 under the name "Maxcure Pharmaceutical, Inc." ("Maxcure") for the purpose of entering into a license agreement with the University of Colorado Health Science Center ("UCHSC") and to pursue a research agreement with UCHSC to further scientific study on a previously FDA-approved pharmaceutical's method of action on various forms of viral illness. On March 31, 2008, Apro Bio Pharmaceutical Corporation, a Utah corporation ("Apro-Utah") was merged into Maxcure and the name of Maxcure was changed to "Apro Bio Pharmaceutical Corporation."

Apro-Utah was originally incorporated under the laws of the state of Utah on February 28, 2006 for the purpose of advancing the underlying licensed scientific art to attain the ability to sell treatments and/or countermeasures commercially to the Federal Government related to bacterial infections.

Except as the context otherwise requires, the terms "Company," "we," "our" or "us" means Across America Financial Services, Inc. and Apro its wholly-owned subsidiary, collectively.

OVERVIEW

We intend to commercialize a broad patent portfolio licensed from the UCHSC. A component of these applications involves use of existing FDA approved drugs to treat a variety of bacterial and viral diseases, biohazards and transplant rejection.

We are the licensee of filed but not yet issued patents related to composition of matter and method of use for an existing FDA approved drug, Alpha 1 Antitrypsin ("AAT"), for treating organ transplantation, including islet transplantation for the treatment of diabetes and bacterial infections including bacterial pneumonia, tuberculosis and anthrax. We have also licensed an existing patent for the treatment of viral infection including HIV, Influenza and potentially the "bird flu" virus.

With the exception of historical information, this document may include forward-looking statements that involve a number of risks and uncertainties. Actual results could differ materially from those anticipated as a result of various risks. There are numerous factors that could contribute to such differences, therefore such projected events and anticipated results are not warranties or guaranties that such events will occur or that the Company will achieve such results. For more information about this corporation and risks involved in the investment of their publicly traded shares, please see the company's website(s), and/or documents filed with the SEC, which are easily accessible in the EDGAR database system.

OTCBB symbol: **AAFS**

**Across America
Financial Services, Inc.**
123 N. College Avenue
Suite 200
Fort Collins, CO 80524

Telephone:
(970) 530-0325

Website:
None listed

Email:
None listed

Active Market Makers

BID	ASK
NITE	NITE
WDCO	WDCO
SPIN	SPIN

Top Market Maker by
volume (Year-to-Date)

Selected Financial Data Comparison

	12 Months Ended MARCH 31, 2008	12 Months Ended MARCH 31, 2007
Total Assets	\$ 17,917	\$ 46,748
Total Liabilities	\$ 427,555	\$ 514,420
Total Expenses	\$ 1,763,141	\$ 1,095,154
Net Income (indicates loss)	\$ (1,812,567)	\$ (1,100,674)

Press Releases

[ACROSS AMERICA FINANCIAL SERVICES, INC. Financials](#) EDGAR Online
Financials (Wed 9:04am)


[ACROSS AMERICA FINANCIAL SERVICES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of](#) EDGAR Online (Mon, Apr 6)

[ACROSS AMERICA FINANCIAL SERVICES, INC. Files SEC form 10-K, Annual Report](#) EDGAR Online (Mon, Mar 30)

[ACROSS AMERICA FINANCIAL SERVICES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement](#) EDGAR Online (Fri, Mar 13)

[ACROSS AMERICA FINANCIAL SERVICES, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events](#) EDGAR Online (Wed, Mar 4)

Three Month Chart



Outstanding Shares:	23,764,567
Estimated Float:	217.91K
52 week high:	2.00
52 week low:	0.20
Average Volume (3-mo.)	174.603